|1.||Fenoy, Soledad: 2 articles (08/2008 - 03/2008)|
|2.||Rueda, Cristina: 2 articles (08/2008 - 03/2008)|
|3.||del Aguila, Carmen: 1 article (08/2008)|
|4.||García-Presedo, Ignacio: 1 article (08/2008)|
|5.||Castro-Hermida, José Antonio: 1 article (08/2008)|
|6.||González-Warleta, Marta: 1 article (08/2008)|
|7.||Mezo, Mercedes: 1 article (08/2008)|
|8.||Mangues, Ramon: 1 article (08/2008)|
|9.||Leon, Javier: 1 article (08/2008)|
|10.||Parreño, Matilde: 1 article (08/2008)|
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
08/01/2008 - "In conclusion, Bobel-24 and derivatives trigger caspase-independent lysosomal and mitochondrial death in all tested human pancreatic cancer lines, irrespective of their degree of apoptotic sensitivity, becoming the only active cytotoxic mechanism in the apoptosis-resistant NP9 line. "
08/01/2008 - "Bobel-24 and derivatives induce caspase-independent death in pancreatic cancer regardless of apoptotic resistance."
|5.||Body Weight (Weight, Body)
08/17/2008 - "Bobel-24 was effective as a prophylactic/therapeutic treatment at the lowest dose (50 mg/kg of body weight); in the group treated with this dose of drug there was a longer prepatent period, a shorter patent period and a lower intensity of oocyst excretion than in the untreated control group, and the differences were all statistically significant (P<0.05). "